Skip to content

Study · Not a test of the peptide alone · 2018

1 result

Neurokinin 3 Receptor Antagonism Reveals Roles for Neurokinin B in the Regulation of Gonadotropin Secretion and Hot Flashes in Postmenopausal Women.

Skorupskaite K, George JT, Veldhuis JD, Millar RP, Anderson RA

Neuroendocrinology5 Apr 2017Cited by 55 (Europe PMC)

PMID28380486 (opens in a new tab)DOI10.1159/000473893 (opens in a new tab)PepBankPUB-28380486
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Kisspeptin-10.

  1. 01HumanNot a test of Kisspeptin-10 aloneNon-randomized trialEfficacy outcome

    In postmenopausal women, intravenous kisspeptin‑10 (0.3 µg/kg) did not affect LH secretion, with or without an NK3R antagonist.

    In plain wordsIn postmenopausal women, kisspeptin‑10 did not change LH release, whether or not they took an NK3R blocker.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeLH secretion after kisspeptin-10, with or without NK3R antagonist
    Study

    n = 11

    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Kisspeptin-10 did not affect LH secretion with or without the NK3R antagonist.
    2 context sentences
    Summary · context
    Eleven postmenopausal women were administered the NK3R antagonist MLE4901 at 40 mg twice daily orally for 7 days.
    Summary · context
    Ten-minute blood sampling for 8 h was performed before and on the last day of NK3R antagonist treatment for luteinising hormone (LH) pulsatility analysis with kisspeptin-10 (0.3 µg/kg i.v. bolus) administered at 6 h on both days.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.